2. Signaling Pathways
  3. Immunology/Inflammation
  4. NO Synthase

NO Synthase

Nitric oxide synthases; NOS

NO Synthase

Related Products

PDF 1.66 MB

Nitric oxide synthases (NOSs) are a family of enzymes catalyzing the production of nitric oxide (NO) from L-arginine. NO synthases catalyze the oxidation of L-arginine to NO and L-citrulline. Mammals contain three NOS isoforms: neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS). NO produced from these different NOS isoforms is involved in a wide range of physiologic functions in the nervous, immune, and cardiovascular systems. Unregulated NO production can lead to pathologic conditions such as stroke, inflammation, and hypertension. Therefore, the control of NOS activity by isoform selective NOS inhibitors has great potential for therapeutic treatments of NO-related diseases.

NO Synthase Isoform Specific Products:

NO Synthase Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-12383
    Pelubiprofen
    		Inhibitor 99.27%
    Pelubiprofen is an orally active anti-inflammatory agent that inhibits COX enzyme activity (with IC50 values of 10.66 and 2.88 μM for COX-1 and COX-2, respectively). Pelubiprofen has significant anti-inflammatory and analgesic effects.
    Pelubiprofen
  • HY-12124
    BBS-4
    		Inhibitor 99.51%
    BBS-4 is a potent and selective inducible nitric oxide synthase (NOS2) dimerization inhibitor, with an IC50 of 0.49 nM. BBS-4 can protect mice from the cardiovascular dysfunction of sepsis.
    BBS-4
  • HY-N7064
    Iminostilbene
    		Inhibitor 99.34%
    Iminostilbene is a chemical precursor of carbamazepine. Additionally, Iminostilbene is an orally active inhibitor of PKM2 (Pyruvate Kinase M2) and COX2 (Cyclooxygenase-2). Iminostilbene exerts its effects by inhibiting PKM2 and its interaction with HIF-1α and STAT3, reducing COX2 and iNOS expression, and decreasing LPS-induced release of IL-1β, IL-6, TNF-α, and MCP-1, thereby suppressing macrophage-mediated inflammatory responses and improving myocardial ischemia/reperfusion (MI/R) injury. Iminostilbene holds promise for research in inflammation regulation, cardiovascular diseases (such as MI/R injury), and macrophage-mediated immune-related diseases.
    Iminostilbene
  • HY-12122A
    AR-C102222 hydrochloride
    		Inhibitor 99.83%
    AR-C102222 hydrochloride is a potent, competitive, orally active and highly selective inducible nitric oxide synthase (iNOS) inhibitor, with an IC50 of 37 nM. AR-C102222 hydrochloride has antinociception and anti-inflammatory activities.
    AR-C102222 hydrochloride
  • HY-N7635
    Oleanolic acid 28-O-β-D-glucopyranoside
    		Inhibitor 99.42%
    Oleanolic acid 28-O-β-D-glucopyranoside (β-D-Glucopyranosyl oleanolate) is an orally active pentacyclic triterpenoid compound. Oleanolic acid 28-O-β-D-glucopyranoside has anti-inflammatory effects. In ulcerative colitis models, Oleanolic acid 28-O-β-D-glucopyranoside can inhibit the inflammatory response, enhance the intestinal epithelial barrier function, and modulate the gut microbiota. Its mechanism of action is related to the PI3K-AKT and MAPK signaling pathways. Oleanolic acid 28-O-β-D-glucopyranoside can be used in the research of diseases such as colitis.
    Oleanolic acid 28-O-β-D-glucopyranoside
  • HY-130452
    NOS1-IN-1
    		Inhibitor
    NOS1-IN-1 is a selective and cell-permeable nNOS inhibitor with a Ki of 120 nM. NOS1-IN-1 exhibits 2617-fold and 325-fold selectivity over eNOS (Ki=39 μM) and iNOS (Ki=325 μM) , respectively. NOS1-IN-1 can be used for the research of neurological disease, including cerebral palsy (CP).
    NOS1-IN-1
  • HY-W074890S
    Palmitoylglycine-d31
    		99.40%
    Palmitoylglycine-d31 is the deuterium labeled Palmitoylglycine.
    Palmitoylglycine-d<sub>31</sub>
  • HY-B2141
    Bendazol
    		Activator 99.78%
    Bendazol is an orally effective antihypertensive agent. Bendazol acts directly on vascular smooth muscle to dilate blood vessels and reduce peripheral resistance, thereby improving blood circulation. Bendazol significantly inhibits the development of myopia in rabbit models. Bendazol can regulate kidney function by increasing the activity of NO synthase in the rat model of nephrogenic hypertension. In addition, Bendazol has an effect on sexual behavior and spermatogenesis in male rats.
    Bendazol
  • HY-141411A
    Zevaquenabant
    		Antagonist 99.64%
    Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD).
    Zevaquenabant
  • HY-115411A
    L-Hydroxy arginine dihydrochloride
    		Substrate 99.27%
    L-Hydroxy arginine dihydrochloride is an intermediate in the catabolism of L-arginine, and is a substrate for NO synthase.
    L-Hydroxy arginine dihydrochloride
  • HY-N2008
    Luteolin 5-O-glucoside
    		Inhibitor ≥98.0%
    Luteolin 5-O-glucoside, a major flavonoidfrom Cirsium maackii, possesses anti-inflammatory activity. Luteolin 5-O-glucoside inhibits LPS-induced NO production and t-BHP-induced ROS generation. Luteolin 5-O-glucoside suppresses the expression of iNOS and COX-2 in macrophages.
    Luteolin 5-O-glucoside
  • HY-153832
    MSU-42011
    		Inhibitor 98.43%
    MSU-42011 is an orally active retinoid X receptor (RXR) agonist. MSU-42011 inhibits the iNOS activity and reduces the expression of p-ERK protein. MSU-42011 has immunomodulatory and antitumor activity.
    MSU-42011
  • HY-N0761A
    trans-Isoferulic acid
    		Inhibitor 99.93%
    trans-Isoferulic acid (trans-3-Hydroxy-4-methoxycinnamic acid) is an aromatic acid isolated from the roots of Clematis florida var. plena. trans-Isoferulic acid exhibits anti-inflammatory activity.trans-isoferulic acid suppresses NO and PGE2 production through the induction of Nrf2-dependent heme oxygenase-1 (HO-1).
    trans-Isoferulic acid
  • HY-N8761
    Kihadanin A
    		Inhibitor
    Kihadanin A (compound 3) is a limonoid NOS3 inhibitor that can be isolated from the methanol extract of Dictamnus dasycarpus root bark. Kihadanin A is useful in the study of hyperuricemia (HUA)[3].
    Kihadanin A
  • HY-100573A
    (E/Z)-Necrosulfonamide
    		Inhibitor 98.84%
    (E/Z)-Necrosulfonamide is a racemic compound of Necrosulfonamide (HY-100573). Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
    (E/Z)-Necrosulfonamide
  • HY-W923189
    Neral
    		Inhibitor
    Neral is a monoterpene compound that has anti-inflammatory and anti-cancer properties. Neral can inhibit TNF-α and IL-6, and it also suppresses inflammatory mediators like pro-IL-1β, iNOS, COX-2, and NLRP-3.
    Neral
  • HY-N8435
    Desoxo-narchinol A
    		Inhibitor 98.0%
    Desoxo-narchinol A is an orally active and potent anti-inflammatory agent. Desoxo-narchinol A can be isolated from the roots and rhizomes of Nardostachys jatamansi. Desoxo-narchinol A can be used for septic shock and inflammatory diseases research.
    Desoxo-narchinol A
  • HY-138564
    NOS-IN-1
    		Inhibitor 98.18%
    NOS-IN-1 is a potent and orally active NO synthase (NOS) isoforms inhibitor with IC50s of 0.1 μM, 1.1 μM, and 0.2 μM for human iNOS (hiNOS), heNOS and hnNOS, respectively.
    NOS-IN-1
  • HY-P0316A
    TP508 TFA
    		Activator 99.54%
    TP508 TFA is a 23-amino acid nonproteolytic thrombin peptide that represents a portion of the receptor-binding domain of thrombin molecule. TP508 TFA activates endothelial NO synthase (eNOS) and stimulates production of NO in human endothelial cells. TP508 TFA activates endothelial cells and stem cells to revascularize and regenerate tissues.
    TP508 TFA
  • HY-126858
    Ambuic acid
    		Inhibitor 98.00%
    Ambuic acid exhibits antimicrobial activity against Staphylococcus aureus, with IC50 of 43.9 μM for strain ATCC 6538. Ambuic acid is an inhbitor for the biosynthesis of cyclic peptide quorum sensing molecules (quormones) in gram-positive bacteria. Ambuic acid exhibits anti-inflammatory activity through ERK/JNK/MAPK signaling pathway.
    Ambuic acid
Cat. No. Product Name / Synonyms Application Reactivity
NO Synthase Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.